AstraZeneca Given Underperform Rating at Credit Suisse (AZN)
AstraZeneca (LON:AZN)‘s stock had its “underperform” rating reiterated by stock analysts at Credit Suisse in a report issued on Monday, Analyst Ratings Network.com reports. They currently have a GBX 3,220 ($51.40) price objective on the stock. Credit Suisse’s target price would suggest a potential upside of 1.05% from the stock’s previous close.
Shares of AstraZeneca (LON:AZN) traded up 0.31% during mid-day trading on Monday, hitting GBX 3186.50. The stock had a trading volume of 1,026,356 shares. AstraZeneca has a 52 week low of GBX 2786.00 and a 52 week high of GBX 3544.50. The stock has a 50-day moving average of GBX 3215.42 and a 200-day moving average of GBX 3252.57. The company’s market cap is £39.895 billion.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group downgraded shares of AstraZeneca from a “hold” rating to an “underperform” rating in a research note to investors on Friday. Separately, analysts at AlphaValue reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,213 ($51.29) price target on the stock. Finally, analysts at Bryan Garnier & Cie reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Monday, October 7th. They now have a GBX 3,620 ($57.79) price target on the stock. Twelve research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of GBX 3,103.98 ($49.55).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.